The tumor-homing portion of the therapeutic chimeric protein, an anti-mesothelin single chain variable fragment (meso-scFv), had high binding affinity to mesothelin [4], which is overexpressed by most ovarian cancers [5,6]. The gene discussed is MSLN; the disease is neoplasm.